Brief: Valneva Reports Positive Results For Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
04/11/2025 06:10
Nov 4 (Reuters) - Valneva SE VLS.PA: VALNEVA REPORTS POSITIVE RESULTS FOR PHASE 1 TRIAL OF SECOND-GENERATION ZIKA VACCINE CANDIDATE VALNEVA SE: IMMUNE RESPONSE SUCCESSFULLY IMPROVED WITH SECOND GENERATION VACCINE CANDIDATE VALNEVA SE: TWO DOSES OF VLA1601 WERE IMMUNOGENIC ACROSS ALL FIVE TREATMENT ARMS INVESTIGATED VALNEVA SE: VLA1601 WAS GENERALLY SAFE AND WELL TOLERATED IN ALL FIVE TREATMENT ARMS VALNEVA SE - DESPITE MEDICAL NEED, REGULATORY PATHWAYS AND MARKET OPPORTUNITIES FOR POTENTIAL ZIKA VACCINES REMAIN UNCERTAIN VALNEVA: WILL ONLY CONSIDER FURTHER POTENTIAL DEVELOPMENT STEPS FOR VLA1601 IF CONCRETE MAJOR PRIVATE AND PUBLIC FUNDING OPPORTUNITIES MATERIALIZE Source text: ID:nGNXb63Gfr Further company coverage: VLS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency